These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 17923855)

  • 21. 8q gain is an independent predictor of poor survival in diagnostic needle biopsies from prostate cancer suspects.
    Ribeiro FR; Jerónimo C; Henrique R; Fonseca D; Oliveira J; Lothe RA; Teixeira MR
    Clin Cancer Res; 2006 Jul; 12(13):3961-70. PubMed ID: 16818693
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genomic alterations in primary cutaneous melanomas detected by metaphase comparative genomic hybridization with laser capture or manual microdissection: 6p gains may predict poor outcome.
    Namiki T; Yanagawa S; Izumo T; Ishikawa M; Tachibana M; Kawakami Y; Yokozeki H; Nishioka K; Kaneko Y
    Cancer Genet Cytogenet; 2005 Feb; 157(1):1-11. PubMed ID: 15676140
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic changes and clonality relationship between primary colorectal cancers and their pulmonary metastases--an analysis by comparative genomic hybridization.
    Jiang JK; Chen YJ; Lin CH; Yu IT; Lin JK
    Genes Chromosomes Cancer; 2005 May; 43(1):25-36. PubMed ID: 15723340
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genome-wide screening for complete genetic loss in prostate cancer by comparative hybridization onto cDNA microarrays.
    Clark J; Edwards S; Feber A; Flohr P; John M; Giddings I; Crossland S; Stratton MR; Wooster R; Campbell C; Cooper CS
    Oncogene; 2003 Feb; 22(8):1247-52. PubMed ID: 12606952
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evidence for gains at 15q and 20q in brain metastases of prostate cancer.
    Wullich B; Riedinger S; Brinck U; Stoeckle M; Kamradt J; Ketter R; Jung V
    Cancer Genet Cytogenet; 2004 Oct; 154(2):119-23. PubMed ID: 15474146
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Deletion at 13q21 is associated with aggressive prostate cancers.
    Dong JT; Chen C; Stultz BG; Isaacs JT; Frierson HF
    Cancer Res; 2000 Jul; 60(14):3880-3. PubMed ID: 10919663
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relative copy number gain of MYC in diagnostic needle biopsies is an independent prognostic factor for prostate cancer patients.
    Ribeiro FR; Henrique R; Martins AT; Jerónimo C; Teixeira MR
    Eur Urol; 2007 Jul; 52(1):116-25. PubMed ID: 17070983
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genomic alterations detected by comparative genomic hybridization in primary lung adenocarcinomas with special reference to the relationship with DNA ploidy.
    Hayashi M; Kawauchi S; Ueda K; Kaneda Y; Oga A; Furuya T; Hamano K; Sasaki K
    Oncol Rep; 2005 Dec; 14(6):1429-35. PubMed ID: 16273235
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Classification of prostatic carcinoma with artificial neural networks using comparative genomic hybridization and quantitative stereological data.
    Mattfeldt T; Gottfried HW; Wolter H; Schmidt V; Kestler HA; Mayer J
    Pathol Res Pract; 2003; 199(12):773-84. PubMed ID: 14989489
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genomic alterations in diffuse-type gastric cancer as shown by high-resolution comparative genomic hybridization.
    Takeno SS; Leal MF; Lisboa LC; Lipay MV; Khayat AS; Assumpção PP; Burbano RR; Smith Mde A
    Cancer Genet Cytogenet; 2009 Apr; 190(1):1-7. PubMed ID: 19264226
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of cytogenetic alterations in stage III serous ovarian adenocarcinoma reveals a heterogeneous group regarding survival, surgical outcome, and substage.
    Partheen K; Levan K; Osterberg L; Helou K; Horvath G
    Genes Chromosomes Cancer; 2004 Aug; 40(4):342-8. PubMed ID: 15188458
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic changes in clinically organ-confined prostate cancer by comparative genomic hybridization.
    Fu W; Bubendorf L; Willi N; Moch H; Mihatsch MJ; Sauter G; Gasser TC
    Urology; 2000 Nov; 56(5):880-5. PubMed ID: 11068328
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oncological control after radical prostatectomy in men with clinical T3 prostate cancer: a single-centre experience.
    Xylinas E; Drouin SJ; Comperat E; Vaessen C; Renard-Penna R; Misrai V; Bitker MO; Chartier-Kastler E; Richard F; Cussenot O; Roupret M
    BJU Int; 2009 May; 103(9):1173-8; discussion 1178. PubMed ID: 19040530
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular cytogenetic analysis of prostatic adenocarcinomas from screening studies : early cancers may contain aggressive genetic features.
    Alers JC; Krijtenburg PJ; Vis AN; Hoedemaeker RF; Wildhagen MF; Hop WC; van Der Kwast TT; Schröder FH; Tanke HJ; van Dekken H
    Am J Pathol; 2001 Feb; 158(2):399-406. PubMed ID: 11159178
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
    Zhao Z; Liu J; Li S; Shen W
    Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Simultaneously detection of genomic and expression alterations in prostate cancer using cDNA microarray.
    Jiang M; Li M; Fu X; Huang Y; Qian H; Sun R; Mao Y; Xie Y; Li Y
    Prostate; 2008 Oct; 68(14):1496-509. PubMed ID: 18366025
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cytogenetic profiles as additional markers to pathological features in clinically localized prostate carcinoma.
    Gallucci M; Merola R; Farsetti A; Orlandi G; Sentinelli S; De Carli P; Leonardo C; Carlini P; Guadagni F; Sperduti I; Cianciulli AM
    Cancer Lett; 2006 Jun; 237(1):76-82. PubMed ID: 16002207
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005.
    Adolfsson J; Garmo H; Varenhorst E; Ahlgren G; Ahlstrand C; Andrén O; Bill-Axelson A; Bratt O; Damber JE; Hellström K; Hellström M; Holmberg E; Holmberg L; Hugosson J; Johansson JE; Petterson B; Törnblom M; Widmark A; Stattin P
    Scand J Urol Nephrol; 2007; 41(6):456-77. PubMed ID: 17934985
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
    Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
    Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The prognostic role of the pathological T2 subclassification for prostate cancer in the 2002 Tumour-Nodes-Metastasis staging system.
    van Oort IM; Witjes JA; Kok DE; Kiemeney LA; Hulsbergen-Van De Kaa CA
    BJU Int; 2008 Aug; 102(4):438-41. PubMed ID: 18336608
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.